Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Clinical trial NCT05603910 · RECRUITING

Trial details

NCT number: NCT05603910
Sponsor: Aaron Wolfson
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Endometrial Carcinoma Unresectable Endometrial Carcinoma

Start date: 2023-04-15
Primary completion: 2029-04-15
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.